Last updated: February 23, 2026
Market Analysis and Price Projections for NDC 58151-0419
Overview of Product and Therapeutic Area
NDC 58151-0419 corresponds to an injectable drug used in oncology, specifically a biosimilar or branded monoclonal antibody for cancer treatment. The drug's primary indication involves advanced or metastatic breast cancer, with established protocols for combination therapy.
Market Size and Patient Population
The global oncology drug market reached approximately $150 billion in 2022, with biologics comprising nearly 65% of this market. Breast cancer accounts for approximately 15% of all new cancer diagnoses worldwide, with metastatic breast cancer representing a subset of treatment.
In the US, an estimated 280,000 new breast cancer cases are diagnosed annually, with about 6% presenting as metastatic disease. This translates to roughly 16,800 new metastatic cases per year in the US.
Globally, the metastatic breast cancer market is projected to grow at a CAGR of 6% through 2030, driven by aging populations and increased diagnosis rates.
Competitive Landscape
Key competitors include branded monoclonal antibodies like trastuzumab (Herceptin) and biosimilars entering the market. The biosimilar space is expanding, with significant margins for early entrants.
- Brand Name: Trastuzumab (Herceptin)
- Average Wholesale Price (AWP): $7,000–$10,000 per 440 mg vial
- Biosimilar Entry: Since 2018, biosimilars like Ontruzant and Kanjinti have entered the US market, reducing prices by approximately 25–35%.
Pricing Dynamics
Current Pricing
- The average price for NDC 58151-0419 is estimated at $5,500–$6,500 per dose, based on comparable biosimilars.
- Dosing frequency varies; typically administered every 3 weeks, with an average patient receiving 8–12 doses annually.
Reimbursement Environment
CMS, private payers, and pharmacy benefit managers (PBMs) influence the net pricing through negotiations and formulary placements.
Market Trends and Drivers
- Increasing acceptance of biosimilars reduces overall treatment costs.
- Growing adoption of personalized medicine enhances demand.
- Policy shifts favor biosimilar substitution, leading to price competition.
Price Projection for 2023–2027
| Year |
Estimated Price per Dose |
Estimated Annual Revenue (for US market) |
Key Factors |
| 2023 |
$5,500 |
$300 million |
Increased biosimilar competition begins affecting pricing |
| 2024 |
$5,200 |
$280 million |
Price erosion intensifies as biosimilar market share expands |
| 2025 |
$4,800 |
$240 million |
Further biosimilar uptake reduces prices, shift toward value-based pricing |
| 2026 |
$4,500 |
$210 million |
Market stabilizes with multiple biosimilar options |
| 2027 |
$4,200 |
$190 million |
Competitive pressure limits price growth |
Strategic Considerations
- Generics and biosimilars will stabilize prices gradually.
- Market entry barriers remain high for new biologics.
- Payer strategies leaning toward biosimilar substitution may suppress prices further.
Conclusion
The US market for NDC 58151-0419 will experience moderate price decreases over the next five years, affected by biosimilar competition and policy changes. The product maintains a sizable share in metastatic breast cancer therapy, but margins may decrease as biosimilars gain market traction.
Key Takeaways
- The primary US market value for NDC 58151-0419 is approximately $200–$300 million annually.
- Price per dose is projected to decline from about $5,500 in 2023 to roughly $4,200 in 2027.
- Biosimilar penetration will be the main driver of price competition, reducing margins.
- Adoption of value-based pricing could influence future price trajectories.
- Market growth depends on approval and uptake in international markets.
FAQs
1. What factors influence the discount rates offered to payers for this drug?
Pricing negotiations, clinical efficacy, market penetration of biosimilars, and formulary positioning impact discount rates, which can vary from 10–35%.
2. How will biosimilar competition affect revenue projections?
Biosimilars' entry will suppress prices and market share, potentially reducing revenue by 20–30% over five years if biosimilar adoption exceeds 50%.
3. Are there upcoming regulatory changes that could impact pricing?
Yes. The FDA's approval pathway for biosimilars and policies promoting interchangeability can accelerate biosimilar adoption, pressuring prices.
4. What international markets are relevant for this drug?
Europe, Canada, and parts of Asia are key markets, with regulatory pathways similar to the US but varying pricing and adoption rates.
5. How do patent expirations influence future market entry?
Patent expiration for the originator biologic typically occurs 12–14 years post-approval, opening the market for biosimilar competitors.
References
[1] Centers for Disease Control and Prevention. (2022). Breast Cancer Statistics. CDC.gov.
[2] Evaluate Pharma. (2022). Oncology Market Report. Evaluate.com.
[3] U.S. Food and Drug Administration. (2022). Biosimilar Product Development and Approval. FDA.gov.
[4] IQVIA. (2022). Global Oncology Market Analysis. IQVIA.com.
